Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Neisseria meningitidis Infections - Overview Neisseria meningitidis Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Neisseria meningitidis Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Neisseria meningitidis Infections - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd Biological E Ltd China National Pharmaceutical Group Corp Chongqing Zhifei Biological Products Co Ltd GlaxoSmithKline Plc ImmunoBiology Ltd Johnson & Johnson MGB Biopharma Ltd Pfizer Inc Sanofi Pasteur SA Serum Institute of India Ltd Wellstat Vaccines LLC Neisseria meningitidis Infections - Drug Profiles (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress MenBioVax - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, B, C] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes A, C, W135] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal [serotypes C, Y] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress meningococcal vaccine 2 - Drug Profile Product Description Mechanism Of Action R&D Progress MGBBP-3 - Drug Profile Product Description Mechanism Of Action R&D Progress NCL-195 - Drug Profile Product Description Mechanism Of Action R&D Progress Neisseria meningitidis [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress PF-06886992 - Drug Profile Product Description Mechanism Of Action R&D Progress TP-10 - Drug Profile Product Description Mechanism Of Action R&D Progress Neisseria meningitidis Infections - Dormant Projects Neisseria meningitidis Infections - Discontinued Products Neisseria meningitidis Infections - Product Development Milestones Featured News & Press Releases Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine) Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial Aug 01, 2013: US FDA expands Novartis' Menveo indication for infants aged two months Feb 25, 2013: CanSinotech submitted CTA of “ACW135Y Meningococcal Conjugate Vaccine” to CFDA Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Menveo Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease Mar 31, 2010: New vaccine can protect travelers against four types of meningitis Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Neisseria meningitidis Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by Biological E Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corp, H1 2018 Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2018 Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H1 2018 Neisseria meningitidis Infections - Pipeline by MGB Biopharma Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H1 2018 Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2018 Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H1 2018 Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H1 2018 Neisseria meningitidis Infections - Dormant Projects, H1 2018 Neisseria meningitidis Infections - Discontinued Products, H1 2018 List of Figures Number of Products under Development for Neisseria meningitidis Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Beijing Minhai Biotechnology Co Ltd Biological E Ltd China National Pharmaceutical Group Corp Chongqing Zhifei Biological Products Co Ltd GlaxoSmithKline Plc ImmunoBiology Ltd Johnson & Johnson MGB Biopharma Ltd Pfizer Inc Sanofi Pasteur SA Serum Institute of India Ltd Wellstat Vaccines LLC